The Implications of Conversion Surgery for Stage Ⅳ Gastric Cancer
Uraoka, M.; Higashida, M.; Ueno, M.; Mineta, S.; Okamoto, Y.; Kubota, H.; Watanabe, Y.; Okada, T.; Tsuruta, A.; Fujiwara, Y.; Ueno, T.
Gan to Kagaku Ryoho. Cancer and ChemoTherapy 45(13): 1797-1799
2018
ISSN/ISBN: 0385-0684 PMID: 30692357 Document Number: 697676
The median survival time(MST)of Stage Ⅳ advanced gastric cancer is reportedly 6-13 months. The standard treatment for Stage Ⅳ gastric cancer is systemic chemotherapy. With advancements in chemotherapy, the number of conversion surgery(CS)is increasing. We evaluated the clinical significance of CS for Stage Ⅳ gastric cancer. We retrospectively examined the clinicopathological variables and oncologic outcomes of 11 patients with Stage Ⅳ gastric cancer who received CS after induction chemotherapy. The MST was 86.4 months in all patients. No significant difference was detected in non-curative clinical factors, pathological type, residual tumor, or Ef-Grade. A longer prognosis could be achieved when an R0 resection was obtained, with excellent histopathologial response, without peritoneal dissemination, and with negative peritoneal lavage cytology. This study provides positive evidence that CS for Stage Ⅳ gastric cancer could be performed safely and could possibly provide longer survival in selected patients.